| Literature DB >> 29552047 |
Mahesh Veerabhadra Attimarad1, Mohammed Abdou Khedr1, Bandar Essa Aldhubiab1.
Abstract
A series of ethyl 2-[2-arylamino-4-(thiophen-2-yl) thiazol-5-yl] acetates (5a-5k) and ethyl 2-[2-(arylhydrazino)-4-(thiophen-2-yl) thiazol-5-yl] acetates (9a-9g) were synthesized and screened for their anti-inflammatory, analgesic, and antioxidant activities. In-vivo test results showed that the compounds with halogen substitution (5c, 5g, 5h, 5i and 5j) at the para position on the 2-aryl amino group exhibited good anti-inflammatory and analgesic activities, similar to that of indomethacin and aspirin, respectively. The ethyl 2-[2-(arylhydrazino)-4-(thiophen-2-yl) thiazol-5-yl] acetates (9a-9g) showed better anti-oxidant activity than compounds 5a-5k, comparable to ascorbic acid. However, these compounds showed moderate to weak anti-inflammatory and analgesic activities. Further, a molecular docking study was performed to predict the possible binding modes on cyclooxygenase-1 (COX-1) and COX-2 for the tested compounds. Good correlation was observed between the anti-inflammatory activity of the compounds and the results of the binding modes in COX-2.Entities:
Keywords: Analgesic; Anti-inflammatory; Antioxidant; Molecular modeling; Synthesis; Thiazole acetates
Year: 2017 PMID: 29552047 PMCID: PMC5843300
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Physical Data of compounds 5a-5k and 9a-9g.
|
|
|
|
|
|
|
|
|
| 2-Cl | C17H15N2O2S2Cl | 378.90 | 1 min | 92 | 90-92 |
|
| 3-Cl | C17H15N2O2S2Cl | 378.90 | 1 min | 89 | 118-120 |
|
| 4-Cl | C17H15N2O2S2Cl | 378.90 | 1 min | 84 | 146-147 |
|
| 2-CH3 | C18H18N2O2S2 | 358.48 | 1 min | 93 | 107-108 |
|
| 3-CH3 | C18H18N2O2S2 | 358.48 | 1 min | 95 | 122-123 |
|
| 4-CH3 | C18H18N2O2S2 | 358.48 | 1 min | 86 | 174-176 |
|
| 4-Br | C17H15N2O2S2Br | 423.44 | 1 min | 73 | 155-156 |
|
| 4-F | C17H15N2O2S2F | 362.44 | 1 min | 83 | 135-136 |
|
| 2,4-Cl2 | C17H14N2O2S2Cl2 | 413.35 | 1.5 min | 90 | 84-85 |
|
| 3-Cl-4-F | C17H14N2O2S2ClF | 396.89 | 1.5 min | 79 | 115-116 |
|
| 4-OCH3 | C18H18N2O3S2 | 374.48 | 1 min | 90 | 153-154 |
|
| H | C18H17O2N3S2 | 371.47 | 40 sec | 91 | 163-164 |
|
| 2-OH | C18H17O3N3S2 | 387.47 | 40 sec | 89 | 152-153 |
|
| 2-Cl | C18H16O2N3S2Cl | 405.91 | 40 sec | 92 | 149-150 |
|
| 4-Cl | C18H16O2N3S2Cl | 405.91 | 40 sec | 79 | 171-172 |
|
| 4-NMe2 | C20H22O2N4S2 | 414.54 | 40 sec | 85 | 184-185 |
|
| 4-OMe | C19H19O3N3S2 | 401.50 | 40 sec | 90 | 146-147 |
|
| 4-OH-3-OMe | C19H19O4N3S2 | 417.49 | 40 sec | 83 | 162-163 |
Compounds 5a-k, 9a-9c were crystallized from absolute ethanol. 9d-9g were crystallized from Ethanol+Acetone. Melting points were determined in an open capillary and are uncorrected. Reactions are monitored on silica gel G TLC plates using solvent system ethyl acetate: n-hexane (3: 7
Scheme 1The synthetic pathway of compounds 5a-5k
Scheme 2The synthetic pathway of compounds 9a-9g
Scheme 3Probable mass fragmentation of componud 5a-5k
Scheme 4Propbable mass fragmantation of compound 9a-9g
Pharmacological activities of compounds 5a-5k and 9a-9g.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Ascorbic acid | - | - | - | - | 3.3±0.07 |
|
| 0.22 ± 0.060 | 66.6 | 22.5 ± 2.54 | 52.54 | 160±2.78 |
|
| 0.21 ± 0.074 | 68.1 | 24.3 ± 4.37 | 49.35 | 190±3.16 |
|
| 0.18 ± 0.069 | 72.7 | 21.8 ± 2.39 | 54.50 | 120±2.95 |
|
| 0.28 ± 0.056 | 54.9 | 32.7 ± 3.57 | 31.8 | 200±1.74 |
|
| 0.20 ± 0.079 | 69.6 | 24.6 ± 4.02 | 48.70 | 255±2.45 |
|
| 0.24 ± 0.074 | 63.4 | 26.3 ± 3.82 | 45.20 | 140±1.98 |
|
| 0.14 ± 0.068 | 78.8 | 20.6 ± 2.65 | 57.00 | 130±1.62 |
|
| 0.15 ± 0.070 | 77.2 | 21.10 ± 3.54 | 56.04 | 95±1.04 |
|
| 0.18 ±0.075 | 72.7 | 29.3 ± 2.54 | 39.10 | 90±1.67 |
|
| 0.17 ±0.047 | 74.3 | 21.60 ± 3.44 | 55.00 | 50±1.50 |
|
| 0.29 ± 0.072 | 50.1 | 25.9 ± 2.24 | 46.00 | 145±2.83 |
|
| 0.31 ± 0.076 | 53.3 | 28.1 ± 2.69 | 41.50 | 8.25±0.29 |
|
| 0.35 ± 0.072 | 46.9 | 30.7 ± 3.00 | 36.00 | 11.75±0.31 |
|
| 0.30 ± 0.079 | 54.5 | 29.3 ± 2.54 | 39.10 | 10.50±0.36 |
|
| 0.32 ± 0.082 | 51.5 | 31.6 ± 3.36 | 34.10 | NT |
|
| 0.40 ± 0.064 | 39.3 | 35.5 ± 4.51 | 26.00 | NT |
|
| 0.48 ± 0.077 | 27.3 | 23.3 ± 4.03 | 51.40 | NT |
|
| 0.42 ± 0.083 | 36.36 | 26.0 ± 3.38 | 45.70 | 10.32±0.21 |
| Indomethacin | 0.12 ± 0.051 | 82.6 | - | - | |
| Aspirin | - | - | 22.00 ± 2.19 | 54.1 |
NT: Not Tested.
value are average of three experiments ± standard deviation.
Docking Results, lipophilic contribution, clash penalties of all compounds on COX-2 with Leadit 2.1.2 software.
|
|
|
|
|
|
|---|---|---|---|---|
| 5a | -14.96 | -16.77 | 8.35 | The ‘’O’’ of acetate moiety interacted with ‘’HN-‘’ of His 90 |
| 5b | -13.99 | -15.48 | 8.64 | The ‘’S’’ atom of thiophene with both –NH of Arg 120 and –OH of Tyr 355 |
| 5c | -20.02 | -18.61 | 6.49 | The ‘’S’’ atom of thiophene with both –NH of Arg 120 and –OH of Tyr 355 |
| 5d | -14.84 | -16.35 | 10.63 | The ‘’O’’ atom of acetate with –OH of Tyr 355 |
| 5e | -16.81 | -15.19 | 9.49 | The 2-arylamino –NH with –C=O of Met 522. |
| 5f | -15.65 | -15.32 | 9.60 | The C=O of acetate with both –NH of Arg 120 and –OH of Tyr 355 |
| 5g | -21.31 | -18.62 | 5.01 | The 2-arylamino –NH with ‘’O’’ of Ser 530 |
| 5h | -21.52 | -19.86 | 5.21 | The 2-arylamino –NH with ‘’O’’ of Ser 350 |
| 5i | -18.74 | -17.38 | 7.21 | The ‘’S’’ atom of thiophene with two –NH of guanidine moiety from Arg 120 |
| 5j | -16.94 | -18.80 | 6.67 | The ‘’S’’ atom of thiophene with both –NH of Arg 120 and –OH of Tyr 355 |
| 5k | -14.31 | -15.90 | 9.81 | The ‘’S’’ atom of thiophene with both –NH of Arg 120 and –OH of Tyr 355 |
| 9a | -14.42 | -14.93 | 12.55 | The benzylidene C=N with both –NH of Arg 120 and –OH of Tyr 355 |
| 9b | -14.86 | -14.55 | 11.26 | The benzylidene C=N with–OH of Tyr 355 |
| 9c | -12.10 | -12.37 | 13.66 | The benzylidene C=N with–OH of Tyr 355 |
| 9d | -5.45 | -13.74 | 14.31 | The benzylidene C=N with–OH of Tyr 355 |
| 9e | -12.37 | -10.32 | 14.08 | The benzylidene C=N with–NH of Arg 120 |
| 9f | -8.96 | -13.49 | 12.48 | The C=O of acetate with both –OH (Tyr 355) and –NH (Arg 120). |
| 9g | -5.79 | -12.48 | 14.60 | The para-OH with C=O group of Gln 192 |
| Indomethacin | -27.25 | -13.64 | 7.31 | COO interacts with both –NH2 (Arg 120) and –OH (Tyr 355). |
Figure 1Docking results of the top active compounds against COX-2 enzyme showing the best binding modes for each compound A) compound 5c. B) compound 5g. C) compound 5h. D) compound 5i. E) compound 5j. F) Indomethacin
Figure 2Docking results of the top active compounds against COX-1 enzyme showing the best binding modes for each compound A) compound 5c. B) compound 5g. C) compound 5h. D) compound 5i. E) compound 5j. F) Indomethacin
The docking scores, lipophilic contribution, clash penalties of the studied compounds on COX -1 with Leadit 2.1.2 software
|
|
|
|
|
|
|---|---|---|---|---|
| 5c | -13.10 | -14.01 | 8.35 | The 2-arylamino-NH with Met 522 |
| 5g | -15.00 | -14.16 | 9.6 | The ‘’S’’ atom of thiophene with –NH of Arg 120 |
| 5h | -13.87 | -15.97 | 8.84 | The ‘’S’’ atom of thiophene with –NH of Arg 120 |
| 5i | -8.98 | -14.63 | 12.17 | The ‘’S’’ atom of thiophene with –NH of Arg 120 |
| 5j | -11.95 | -14.21 | 9.01 | The 2-arylamino -NH with Met 522 |
| Indomethacin | -22.39 | -13.23 | 7.22 | COO interacts with both –NH and NH2 Arg 120 |
Figure 3The lipophilicity map of the binding site of COX-2 enzyme with compounds 5a, 5g, 5h, 5i and 5j. The more lipophilic parts (in red), hydrophilic parts (in blue) and moderate lipophilic parts (in orange